AKT1 and head and neck squamous cell carcinoma: Seiwert et al. showed that dual blockade of SU11274 (c-MET inhibitor) and erlotinib (EGFR inhibitor) in HNSCC lines produce greater-than-additive inhibition of cell growth via erbB3/AKT signaling [86].